Next Article in Journal
Novel Sulfamethoxazole Ureas and Oxalamide as Potential Antimycobacterial Agents
Next Article in Special Issue
ABC Transport Proteins in Cardiovascular Disease—A Brief Summary
Previous Article in Journal
Choerosponins A and B, Two New Cytotoxic Bridged-Ring Ketones and the Determination of Their Absolute Configurations
Previous Article in Special Issue
New Roads Leading to Old Destinations: Efflux Pumps as Targets to Reverse Multidrug Resistance in Bacteria
Open AccessReview

Harnessing Solute Carrier Transporters for Precision Oncology

1
Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
2
Department of Pharmaceutics, University of Washington, Seattle, WA 98195, USA
3
Division of Oncology, Department of Medicine, University of Washington, Seattle, WA 98195 USA
4
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Maria Emília de Sousa
Molecules 2017, 22(4), 539; https://doi.org/10.3390/molecules22040539
Received: 27 February 2017 / Revised: 21 March 2017 / Accepted: 22 March 2017 / Published: 28 March 2017
(This article belongs to the Special Issue Can Membrane Transporters Contribute to Drug Discovery?)
Solute Carrier (SLC) transporters are a large superfamily of transmembrane carriers involved in the regulated transport of metabolites, nutrients, ions and drugs across cellular membranes. A subset of these solute carriers play a significant role in the cellular uptake of many cancer therapeutics, ranging from chemotherapeutics such as antimetabolites, topoisomerase inhibitors, platinum-based drugs and taxanes to targeted therapies such as tyrosine kinase inhibitors. SLC transporters are co-expressed in groups and patterns across normal tissues, suggesting they may comprise a coordinated regulatory circuit serving to mediate normal tissue functions. In cancer however, there are dramatic changes in expression patterns of SLC transporters. This frequently serves to feed the increased metabolic demands of the tumor cell for amino acids, nucleotides and other metabolites, but also presents a therapeutic opportunity, as increased transporter expression may serve to increase intracellular concentrations of substrate drugs. In this review, we examine the regulation of drug transporters in cancer and how this impacts therapy response, and discuss novel approaches to targeting therapies to specific cancers via tumor-specific aberrations in transporter expression. We propose that among the oncogenic changes in SLC transporter expression there exist emergent vulnerabilities that can be exploited therapeutically, extending the application of precision medicine from tumor-specific drug targets to tumor-specific determinants of drug uptake. View Full-Text
Keywords: solute carrier transporters; drug transport; chemotherapy; precision medicine; targeted therapy; SLC35F2; Survivin; YM155; precision oncology solute carrier transporters; drug transport; chemotherapy; precision medicine; targeted therapy; SLC35F2; Survivin; YM155; precision oncology
MDPI and ACS Style

Nyquist, M.D.; Prasad, B.; Mostaghel, E.A. Harnessing Solute Carrier Transporters for Precision Oncology. Molecules 2017, 22, 539. https://doi.org/10.3390/molecules22040539

AMA Style

Nyquist MD, Prasad B, Mostaghel EA. Harnessing Solute Carrier Transporters for Precision Oncology. Molecules. 2017; 22(4):539. https://doi.org/10.3390/molecules22040539

Chicago/Turabian Style

Nyquist, Michael D.; Prasad, Bhagwat; Mostaghel, Elahe A. 2017. "Harnessing Solute Carrier Transporters for Precision Oncology" Molecules 22, no. 4: 539. https://doi.org/10.3390/molecules22040539

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop